TREM2-APOE Axis Dissociation for Selective DAM Activation

Backfill, Etl V1

ID: h-5b378bd3

Hypothesis

TREM2-APOE Axis Dissociation for Selective DAM Activation

The TREM2-APOE axis represents a critical signaling hub governing microglial function in the neurodegenerating brain, and pharmacological dissociation of this axis offers a strategy to selectively activate beneficial disease-associated m.

🧬 TREM2-APOE axis🩺 neurodegeneration🎯 Composite 89%💱 $0.64▼10.9%validated

🔴 Alzheimer's Disease 🔮 Lysosomal / Autophagy 🔬 Microglial Biology 🔥 Neuroinflammation

EvidencePending (0%)📖 35 cit🗣 1 debates✓ 8 support✗ 6 oppose

⚠ Low Validation Senate Quality Gates →

🏆 ChallengeResolve: TREM2-APOE Axis Dissociation for Selective DAM Activation$1K →

☰ Compare ⚔️ Duel ⚛️ Collide

📄 Export LaTeX

arXiv Preprint NeurIPS Nature Methods PLOS ONE

📖 Export BibTeXinteract with this hypothesis

Composite89%

🧪 Overview

Mechanistic Overview

The TREM2-APOE axis represents a critical signaling hub governing microglial function in the neurodegenerating brain, and pharmacological dissociation of this axis offers a strategy to selectively activate beneficial disease-associated microglia (DAM) while attenuating pathological lipid metabolism and inflammatory dysregulation. TREM2, a surface receptor expressed predominantly on microglia and macrophages, signals through the adaptor protein DAP12 (TYROBP), which contains an immunoreceptor tyrosine-based activation motif. This TREM2-DAP12 signaling cascade activates downstream pathways including SYK kinase, phosphoinositide 3-kinase (PI3K), and phospholipase C gamma (PLCG2), driving transcriptional programs that promote cell survival, process motility, and phagocytic capacity. Under physiological conditions, TREM2-APOE signaling facilitates the clearance of cellular debris, myelin debris, and apoptotic cells, functions essential for CNS homeostasis.

...

Mechanistic Overview

The TREM2-APOE axis represents a critical signaling hub governing microglial function in the neurodegenerating brain, and pharmacological dissociation of this axis offers a strategy to selectively activate beneficial disease-associated microglia (DAM) while attenuating pathological lipid metabolism and inflammatory dysregulation. TREM2, a surface receptor expressed predominantly on microglia and macrophages, signals through the adaptor protein DAP12 (TYROBP), which contains an immunoreceptor tyrosine-based activation motif. This TREM2-DAP12 signaling cascade activates downstream pathways including SYK kinase, phosphoinositide 3-kinase (PI3K), and phospholipase C gamma (PLCG2), driving transcriptional programs that promote cell survival, process motility, and phagocytic capacity. Under physiological conditions, TREM2-APOE signaling facilitates the clearance of cellular debris, myelin debris, and apoptotic cells, functions essential for CNS homeostasis. In Alzheimer's disease and related tauopathies, the TREM2-APOE axis becomes co-opted to drive a phenotypic shift toward dysfunctional microglia exhibiting impaired phagolysosomal processing, lipid droplet accumulation, and pro-destructive inflammatory skewing ^[1].

APOE exists in three major human isoforms—APOE2, APOE3, and APOE4—arising from two SNPs at codons 112 and 158, with APOE4 conferring substantially increased Alzheimer's risk through altered lipid-binding properties, differential interaction kinetics with TREM2, and distinct effects on microglial metabolic and inflammatory states ^[2]. When TREM2 is agonized in the presence of robust APOE signaling, the resulting transcriptional activation promotes both phagocytic uptake and lipid accumulation, with the latter driving foam cell formation that paradoxically impairs clearance capacity. APOE-mediated provision of cholesterol and phospholipids to microglia via TREM2 signaling creates a feedforward loop wherein increased lipid uptake fuels inflammatory cytokine production, which in turn stimulates additional APOE expression by astrocytes and microglia ^[2].

The proposed therapeutic strategy dissociates these intertwined signals by agonistic activation of TREM2 to drive beneficial phagocytic programs while simultaneously blocking or attenuating APOE signaling to prevent lipid accumulation and inflammatory skewing. TREM2 can signal independently of APOE interaction through alternative ligands or through ligand-independent activation, suggesting that pharmacologic agonism of TREM2 can bypass the need for APOE-mediated receptor engagement. Alternatively, selective modulation of downstream TREM2 effectors—such as SYK or the PI3K pathway—might permit activation of phagocytic programs without triggering the APOE-dependent transcriptional state that drives lipid accumulation.

Molecular and Cellular Rationale

TREM2-APOE Axis Gene Expression Context

TREM2 — Expression in the Healthy Brain

TREM2 is expressed almost exclusively in cells of the myeloid lineage within the central nervous system. Single-nucleus RNA-seq (snRNA-seq) data from the Allen Brain Atlas (ABA) and the NIH Brain Initiative confirm that TREM2 transcripts are detected at high levels in microglia isolated from adult human cortex, hippocampus, and cerebellum. In the GTEx consortium's brain tissue dataset, TREM2 is among the most differentially expressed microglial genes, with mean expression of ~4–6 transcripts per million (TPM) in bulk cortical samples. TREM2 expression is highest in the hippocampus (CA1 and dentate gyrus) and prefrontal and entorhinal cortices—the regions most vulnerable to early AD pathology—and comparatively lower in the cerebellum, consistent with that region's relative sparing in AD. Cell-type resolution from snRNA-seq of healthy human prefrontal cortex (SEA-AD dataset) assigns TREM2 to homeostatic microglia co-expressing CX3CR1, P2RY12, CSF1R, and HEXB. TREM2 is undetectable in astrocytes, neurons, oligodendrocytes, or endothelial cells by snRNA-seq.

APOE — Expression and Isoform Specificity

APOE is predominantly expressed by astrocytes in the healthy brain, with bulk RNA-seq from GTEx reporting APOE as one of the top 20 most abundant transcripts in human frontal cortex tissue (~200–400 TPM). SnRNA-seq from healthy donors resolves APOE to a discrete "gray matter astrocyte" subpopulation also expressing GFAP, ALDH1L1, AQP4, and SLC1A2 (EAAT2). The three APOE isoforms—APOE2 (Cys₁₃₂/Cys₁₅₈), APOE3 (Cys₁₃₂/Arg₁₅₈), and APOE4 (Arg₁₃₂/Arg₁₅₈)—arise from a single gene (chromosome 19q13.32) via two SNPs at codons 112 and 158. Allelic expression is approximately equal across isoforms at the mRNA level in bulk brain tissue (GTEx), but APOE4 protein shows reduced association with high-density lipoprotein-like particles compared to APOE3 and APOE2 at the protein level ^[2].

DAP12 (TYROBP) — The Signaling Bridge

TYROBP (DAP12) serves as the obligate adaptor for TREM2 signaling and is restricted to microglia and macrophages in the CNS. SnRNA-seq from human prefrontal cortex (SEA-AD) places TYROBP within the same microglial homeostatic cluster as TREM2, with strong co-expression of CSF1R, SYK, and downstream effectors including PLCG2 and PI3K pathway members. TYROBP expression is relatively constant across brain regions in healthy tissue but becomes dysregulated in disease states.

Cell-Type Specificity in Neurodegeneration — The DAM Transition

Single-cell and snRNA-seq from AD-affected human brains (SEA-AD, ROS/MAP, Mayo Clinic AD snRNA-seq dataset) reveal a profound shift in the TREM2-APOE axis cellular landscape. In mild cognitive impairment (MCI) and AD brains, a subset of microglia undergoes a phenotypic transition from homeostatic TREM2⁺ cells to disease-associated microglia (DAM). The DAM program is characterized by:

Upregulation of TREM2 (2–5× enrichment in DAM vs. homeostatic microglia in snRNA-seq from AD hippocampus)
Upregulation of lipid-processing genes including APOE, ABCA1, ABCG1, LPL, LIPA, and LDLR
Downregulation of homeostatic genes P2RY12, P2RY13, CX3CR1, and TMEM119

The SEA-AD dataset (temporal cortex, n=84 donors spanning cognitively normal to AD dementia) quantifies this shift: TREM2⁺ APOE⁺ double-positive microglia expand from ~5% of all microglia in cognitively normal elderly to ~25–30% in AD brains, with the proportion correlating with Braak stage and CERAD cortical neuritic plaque density. TREM2 loss-of-function variants (including R47H and R62H, associated with AD and FTD) prevent the DAM transition entirely, resulting in microglia that accumulate lipid droplets, show impaired phagolysosomal function, and display a pro-inflammatory rather than pro-resolving cytokine signature ^[3]. This confirms that TREM2 is the gatekeeper of the DAM program and implicates APOE as the ligand driving the lipid-metabolic shift within this state.

APOE4 Isoform Effects on Microglial Gene Expression

RNA-seq from APOE4-knock-in vs. APOE3-knock-in humanized mouse models and postmortem human brain tissue reveals isoform-specific gene expression signatures. Compared to APOE3, APOE4-expressing microglia show:

Upregulated TREM2 and TYROBP (compensatory, possibly reflecting impaired downstream signaling)
Elevated APOE itself (autocrine feedback loop)
Increased expression of IL1B, TNF, and NLRP3 inflammasome components (pro-inflammatory skew)
Suppressed P2RY12 and TMEM119 (accelerated homeostatic gene loss)
Induction of CH25H (cholesterol 25-hydroxylase) and CYP27A1, reflecting altered sterol metabolism
Differential expression of PLCG2, an AD GWAS hit that interacts with the TREM2-DAP12 cascade

Allen Brain Atlas human tissue in situ hybridization (ISH) confirms that APOE mRNA is elevated in astrocytes surrounding amyloid plaques in AD brains, with a spatial gradient highest within ~50 µm of plaque cores, consistent with a reactive astrocytic response ^[4].

Downstream Pathway Context

The TREM2-DAP12 (TYROBP) axis signals through SYK, which activates PI3K and PLCG2. Key co-expressed and downstream genes include:

PLCG2 — upregulated in DAM; contains AD-protective coding variants
CSF1R — co-expressed with TREM2 in homeostatic microglia; involved in microglial survival
HEXB, CX3CR1, P2RY12 — homeostatic microglial markers suppressed in DAM
ABCA1, ABCG1, LDLR — lipid metabolism genes co-induced with APOE in DAM
LIPA, LPL, FABP5 — lysosomal and fatty acid genes upregulated in DAM, reflecting lipid droplet accumulation
C1QA, C1QB, C1QC — complement components induced in DAM via TREM2-dependent signaling
SYK — kinase directly activated by DAP12 phosphorylation
MAPK1/MAPK3 (ERK1/2) — canonical downstream targets of the TREM2-PI3K axis

In Parkinson's disease and ALS brains, TREM2 expression in microglia is similarly upregulated in proximity to neurodegeneration, with single-cell studies from the NSW Brain Bank (PD substantia nigra) and ALS motor cortex confirming DAM-like transcriptional programs ^[5]. Frontotemporal dementia with GRN (progranulin) mutations shows TREM2⁺ microglia exhibiting hyperinflammatory phenotypes with elevated APOE and TREM2 but impaired lipid clearance, suggesting that TREM2-APOE axis dysregulation is a transdiagnostic feature of frontotemporal neurodegeneration.

Regional Vulnerability and Therapeutic Implications

The regional pattern of TREM2-APOE axis activity maps onto known vulnerability gradients in AD. The hippocampus (particularly CA1 and subiculum), entorhinal cortex, and prefrontal cortex show the highest TREM2/APOE co-expression in disease states and the greatest DAM enrichment in SEA-AD snRNA-seq. The cerebellum and primary visual cortex are relatively spared and show lower baseline TREM2 expression, a regional gradient mirrored in TYROBP transcript abundance across brain regions in GTEx. Single-cell evidence indicates that partial TREM2 agonism can drive beneficial aspects of the DAM program (enhanced phagocytosis, process motility, cell survival) without full activation of lipid droplet accumulation and inflammatory skewing that requires concurrent APOE engagement ^[3]. The PLCG2 locus represents a parallel therapeutic node at the same signaling hub, and co-modulation of TREM2-PLCG2 may offer synergistic benefit.

Evidence Supporting the Hypothesis

The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia across multiple neurodegenerative contexts ^[1].

Loss of TREM2 function increases amyloid seeding while reducing plaque-associated ApoE, demonstrating that TREM2 is required for APOE deposition at amyloid plaques and that this accumulation reflects active TREM2-dependent recruitment rather than passive proximity ^[6].

STRING protein interaction analysis reveals high-confidence physical associations: APOE-TREM2 (score 0.986), APOE-CLU (score 0.991), and CLU-TREM2 (score 0.954), indicating these three proteins form a tightly integrated functional module.

Pathway enrichment analysis identifies 'Regulation of amyloid-beta clearance' (p=4.1e-08, odds ratio 713.5) as a top enriched term for this gene set.

Increasing TREM2-WT expression modestly reduces soluble phosphorylated tau levels and mildly preserves neuronal integrity in the PS19 tauopathy mouse model, with single-cell RNA sequencing confirming that TREM2-WT robustly enhances microglial activation ^[3].

APOE aggregation in microglia has been identified as an initiating event in Alzheimer's disease pathology through seeding of β-amyloidosis, directly implicating the APOE-microglial interface as a causal node rather than a downstream correlate ^[4].

Contradictory Evidence, Caveats, and Failure Modes

APOE has multiple context-dependent functions essential for synaptic repair and neuronal health; global APOE antagonism could impair these critical homeostatic functions, particularly given that even individuals without APOE4 risk alleles exhibit APOE-dependent microglial regulation ^[2].

The hypothesis does not fully address how axis dissociation would operate differently across APOE genotypes; APOE4 homozygotes may experience particularly pronounced effects from APOE blockade given their baseline altered APOE function relative to APOE3 carriers ^[2].

APOE aggregation in microglia initiates amyloid seeding, meaning that APOE blockade could either be beneficial (preventing pathological aggregation) or harmful (disrupting TREM2-dependent APOE clearance functions) depending on disease stage ^[4].

The APOE-microglia axis exhibits functional divergence with both protective and pathogenic roles depending on context, making the net effect of axis dissociation difficult to predict without stage-specific and isoform-specific experimental data ^[2].

The TREM2-APOE binding interface remains incompletely characterized; APOE has multiple receptors with redundant functions, making axis dissociation pharmacologically underspecified without identification of the precise interaction surface to target.

Complete blockade of APOE may disrupt physiological lipid transport throughout the CNS, with potential consequences for neuronal membrane maintenance, synaptic plasticity, and myelin integrity that are currently incompletely characterized ^[7].

Long-term consequences of sustained microglial activation in the absence of APOE feedback are unknown and could include adaptive changes in microglial biology that diminish therapeutic benefit or promote alternative pathological pathways.

Clinical and Translational Relevance

The APOE4 allele represents the single greatest genetic risk factor for sporadic Alzheimer's disease, conferring approximately four-fold increased risk in heterozygous carriers and twelve-fold increased risk in homozygotes ^[2]. Even individuals without APOE4 risk alleles exhibit progressive APOE accumulation at amyloid plaques and APOE-dependent microglial dysregulation, indicating that APOE-mediated pathology extends beyond APOE4 carriers to the broader Alzheimer's population ^[6]. TREM2 agonism alone carries the risk of promoting APOE-driven lipid accumulation and inflammatory skewing that may attenuate potential benefits, while APOE suppression or neutralization risks impairing physiological TREM2 signaling that supports beneficial phagocytosis and microglial survival ^[3].

Pharmacological implementation would require simultaneous or sequential administration of a TREM2 agonist and an APOE antagonist, with the latter potentially comprising an antibody targeting APOE, a small molecule disrupting APOE-TREM2 interaction, or an antisense oligonucleotide reducing APOE expression. Timing of administration is critical: earlier intervention during prodromal or asymptomatic stages is likely to provide maximal benefit before microglial dysfunction becomes entrenched. Blood-brain barrier penetration of candidate therapeutic agents represents a significant pharmacological challenge for both TREM2-targeted and APOE-targeted approaches. No clinical trial is yet attached to this hypothesis; translational diligence on exposure, tolerability, and endpoint selection remains to be completed, particularly given that adjacent pathway programs have encountered these obstacles.

Experimental Predictions and Validation Strategy

Perturbation experiment: Combined TREM2 agonism and APOE blockade in PS19 or 5xFAD mouse models should reduce lipid droplet accumulation in DAM (measured by BODIPY staining and lipidomics) and enhance phagocytic clearance (measured by pHrodo-labeled substrate uptake), with single-cell RNA-seq confirming selective induction of the pro-phagocytic DAM transcriptional signature without full activation of the lipid-inflammatory module ^[3].

Rescue arm: Restoring APOE signaling after TREM2 agonism should revert the selective DAM state back toward lipid-laden dysfunctional microglia, confirming that APOE blockade rather than TREM2 agonism alone is responsible for the selective phenotype.

Genetic stratification: The experiment must be repeated across APOE2, APOE3, and APOE4 knock-in backgrounds to determine whether dissociation efficacy and safety differ by isoform ^[2].

Human validation: Induced pluripotent stem cell-derived microglia from APOE3/3 and APOE4/4 donors should be used to confirm that axis dissociation replicates the selective DAM phenotype observed in mouse models, as many microglial neurodegeneration programs fail to translate across species.

Disconfirming threshold: If combined TREM2 agonism plus APOE blockade fails to separate phagocytic function from lipid droplet accumulation in at least two independent model systems, or if APOE blockade produces detectable synaptic or myelin pathology at therapeutic doses, the mechanistic premise of the hypothesis should be considered falsified.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["TREM2-APOE Axis<br/>Pharmacological Dissociation"]
    B["TREM2 Agonism<br/>Beneficial Signaling"]
    C["APOE Effect Blockade<br/>Prevent Lipid Accumulation"]
    D["Selective DAM Activation<br/>Phagocytosis Without Inflammation"]
    E["Beneficial Phagocytosis<br/>Amyloid Clearance"]
    F["No APOE-Driven<br/>Lipid Accumulation"]
    G["No Inflammatory Skewing"]
    H["Neuroprotection<br/>Disease Modification"]
    A --> B
    A --> C
    B --> D
    C --> D
    D --> E
    E --> H
    F --> H
    G --> H
    style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
    style H fill:#1b5e20,stroke:#81c784,color:#81c784

⚖️ Evidence

⚖️ Evidence Matrix8 supports6 contradicts

Supports

TREM2-APOE pathway drives transcriptional phenotype of dysfunctional microglia

PMID:28930663

Supports

Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE

PMID:30617257

Supports

STRING protein interaction: APOE-TREM2 (score 0.986)

Supports

STRING protein interaction: APOE-CLU (score 0.991)

Supports

STRING protein interaction: CLU-TREM2 (score 0.954)

Supports

Enrichment: 'Regulation of amyloid-beta clearance' (p=4.1e-08, odds ratio 713.5)

Supports

TREM2 agonism in the presence of APOE signaling promotes lipid accumulation through enhanced cholesterol and phospholipid uptake, driving foam cell formation that impairs phagolysosomal processing.

PMID:41648425

Supports

TREM2 agonism in the presence of APOE signaling promotes lipid accumulation through enhanced cholesterol and phospholipid uptake, driving foam cell formation that impairs phagolysosomal processing.

PMID:29705945

Contradicts

APOE has multiple, context-dependent functions essential for synaptic repair and neuronal health; global APOE antagonism could impair these critical homeostatic functions

Contradicts

ApoE4 vs. ApoE3/2 complexity—the hypothesis does not address how dissociation would work differently across APOE genotypes

Contradicts

Apolipoprotein E aggregation in microglia initiates Alzheimer's disease pathology by seeding β-amyloidosis

PMID:39419029

Contradicts

APOE-microglia axis is described as 'functional divergence' with both protective and pathogenic roles depending on context

PMID:40722268

Contradicts

TREM2-APOE binding interface is unknown; APOE has multiple receptors with redundant functions making axis dissociation pharmacologically underspecified

Contradicts

TREM2 agonism promotes APOE production—combining TREM2 agonism with APOE blockade may be self-defeating

📖 Linked Papers (5)Export BibTeX ↗

Enhancing TREM2 expression activates microglia and modestly mitigates tau pathology and neurodegeneration.

Journal of neuroinflammation (2025) · PubMed:40122810 ↗

No figures

Enhancing TREM2 expression activates microglia and modestly mitigates tau pathology and neurodegeneration.

Journal of neuroinflammation (2025) · PubMed:40122810 ↗

No figures

Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disease.

International journal of molecular sciences (2020) · PubMed:33182554 ↗

No figures

Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disease.

International journal of molecular sciences (2020) · PubMed:33182554 ↗

No figures

Multiple Sclerosis Pathology.

Cold Spring Harbor perspectives in medicine (2018) · PubMed:29358320 ↗

No figures

🏥 Translation

🧬 3D Protein Structure — TREM2-APOE

No curated PDB or AlphaFold mapping for TREM2-APOE yet. Search RCSB →

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for TREM2-APOE axis from GTEx v10.

💉 Clinical Trials (1)

0
Active

0
Completed

0
Total Enrolled

NA
Highest Phase

Gut Microbiota and Parkinson's DiseaseNA

UNKNOWN·NCT03710668 · Alaa E Ahmed

Over the past decade, experimental data has suggested a complex and bidirectional interaction between the gastrointestinal (GI) tract and the central nervous system (CNS), the so-called "Gut- Brain ax

Parkinson Disease

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for TREM2-APOE axis →

No DepMap CRISPR Chronos data found for TREM2-APOE axis.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

💰 Estimated Development

Cost

$0

Timeline

—

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend

↘

Falling

7d Momentum

▼ 1.4%

Volatility

Low

0.0199

Events (7d)

3

Price History

▼10.9%

💾 Resource Usage

LLM Tokens

100

$0.0005

Total Cost

$0.0005

🔮 Predictions

🔎 Predictions vs Observations1 predictions · 0 with recorded observations

Prediction	Predicted	Observed	Status	Conf
If hypothesis is true, intervention targeting TREM2-APOE axis will achieve: TREM2 agonism or modulation reduces microglial dysregulation, decreases neurodegeneration markers, and improves cognitive ou	TREM2 agonism or modulation reduces microglial dysregulation, decreases neurodegeneration markers, and improves cognitive outcomes in animal models or human iPS	— no observation —	open	0.89

🔮 Falsifiable Predictions (1)

openconf 89%

If hypothesis is true, intervention targeting TREM2-APOE axis will achieve: TREM2 agonism or modulation reduces microglial dysregulation, decreases neurodegeneration markers, and improves cognitive outcomes in animal models or human iPSC systems within 12-24 months

Predicted outcome: TREM2 agonism or modulation reduces microglial dysregulation, decreases neurodegeneration markers, and improves cognitive outcomes in animal models or

Falsification: TREM2 agonism fails to reduce neurodegeneration markers or improve cognitive outcomes in validated models

📖 References (7)

The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases.
Krasemann S et al.. Immunity (2017)
PubMed↗DOI↗
The APOE-Microglia Axis in Alzheimer's Disease: Functional Divergence and Therapeutic Perspectives-A Narrative Review.
Brain sciences (2025)
PubMed↗DOI↗
Enhancing TREM2 expression activates microglia and modestly mitigates tau pathology and neurodegeneration.
["Chen Kai" et al.. Journal of neuroinflammation (2025)
PubMed↗
Apolipoprotein E aggregation in microglia initiates Alzheimer's disease pathology by seeding β-amyloidosis.
Kaji S et al.. Immunity (2024)
PubMed↗DOI↗
Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disease.
Marogianni C et al.. International journal of molecular sciences (2020)
PubMed↗DOI↗
Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE.
["Parhizkar Samira" et al.. Nature neuroscience (2019)
PubMed↗DOI↗
Multiple Sclerosis Pathology.
Lassmann H. Cold Spring Harbor perspectives in medicine (2018)
PubMed↗DOI↗

▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate

source	v1_phase_c_backfill
origin_type	gap_debate
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

0%

Debates

0

Incoming

0

Outgoing

0

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

Composite		89%
Mech.		70%
Evidence		65%
Novelty		78%
Feasibility		35%
Impact		68%
Druggability		28%
Safety		42%
Competition		72%
Data avail.		60%
Reproducibility		58%

📗 Cite This Artifact

TREM2-APOE Axis Dissociation for Selective DAM Activation

🧪 Overview

Mechanistic Overview

Mechanistic Overview

Molecular and Cellular Rationale

TREM2-APOE Axis Gene Expression Context

TREM2 — Expression in the Healthy Brain

APOE — Expression and Isoform Specificity

DAP12 (TYROBP) — The Signaling Bridge

Cell-Type Specificity in Neurodegeneration — The DAM Transition

APOE4 Isoform Effects on Microglial Gene Expression

Downstream Pathway Context

Regional Vulnerability and Therapeutic Implications

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

🧬 Mechanism

⚖️ Evidence

🏥 Translation

🧬 3D Protein Structure — TREM2-APOE

💉 Clinical Trials (1)

🏆 Tournament

🏆 Arenas / Elo

📊 Market Indicators

💾 Resource Usage

🔮 Predictions

📖 References (7)

🧬 Related Hypotheses — same target / disease (20)

💬 Discussion

📗 Cite This Artifact

TREM2-APOE Axis Dissociation for Selective DAM Activation

🧪 Overview

Mechanistic Overview

Mechanistic Overview

Molecular and Cellular Rationale

TREM2-APOE Axis Gene Expression Context

TREM2 — Expression in the Healthy Brain

APOE — Expression and Isoform Specificity

DAP12 (TYROBP) — The Signaling Bridge

Cell-Type Specificity in Neurodegeneration — The DAM Transition

APOE4 Isoform Effects on Microglial Gene Expression

Downstream Pathway Context

Regional Vulnerability and Therapeutic Implications

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

🧬 Mechanism

⚖️ Evidence

🏥 Translation

🧬 3D Protein Structure — TREM2-APOE

💉 Clinical Trials (1)

🏆 Tournament

🏆 Arenas / Elo

📊 Market Indicators

💾 Resource Usage

🧭 Related

activates (14)

associated with (2)

biomarker for (4)

causes (6)

enhances (1)

homologous to (1)

inhibits (1)

modulates (6)

prevents (1)

protective against (2)

regulates (8)

risk factor for (1)

targets (1)

therapeutic target for (2)

🔮 Predictions

📖 References (7)

🧬 Related Hypotheses — same target / disease (20)

💬 Discussion